Trials / Conditions / Unresectable Urothelial Carcinoma

Unresectable Urothelial Carcinoma

12 registered clinical trials studyying Unresectable Urothelial Carcinoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial C NCT07221942	Fox Chase Cancer Center	Phase 2
Recruiting	A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Tr NCT06524544	National Cancer Institute (NCI)	Phase 3
Recruiting	Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite NCT06439836	National Cancer Institute (NCI)	Phase 1
Recruiting	Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285	Mayo Clinic	Phase 2
Recruiting	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381	Mayo Clinic	Phase 1 / Phase 2
Active Not Recruiting	Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma NCT05154994	University of Utah	Phase 1
Active Not Recruiting	ARID1A and/or KDM6A Mutation and CXCL13 Expression NCT04953104	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942	National Cancer Institute (NCI)	Phase 1
Recruiting	Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer NCT04878029	Emory University	Phase 1
Terminated	Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) NCT04003610	Incyte Corporation	Phase 2
Completed	Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary NCT00942331	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney NCT00365157	National Cancer Institute (NCI)	Phase 1 / Phase 2